Leerink Partnrs Has Bullish Outlook for EWTX FY2026 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Investment analysts at Leerink Partnrs lifted their FY2026 EPS estimates for shares of Edgewise Therapeutics in a note issued to investors on Monday, December 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($1.91) per share for the year, up from their prior estimate of ($2.04). The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share.

A number of other analysts also recently issued reports on the stock. Piper Sandler boosted their price objective on shares of Edgewise Therapeutics from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Wedbush boosted their price target on Edgewise Therapeutics from $44.00 to $45.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Truist Financial increased their price target on Edgewise Therapeutics from $33.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $32.00 price objective on shares of Edgewise Therapeutics in a report on Tuesday, September 17th. Finally, Evercore ISI increased their target price on Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Edgewise Therapeutics presently has an average rating of “Buy” and an average target price of $43.17.

Edgewise Therapeutics Stock Down 1.3 %

Shares of EWTX traded down $0.38 during midday trading on Thursday, reaching $29.63. 104,911 shares of the stock were exchanged, compared to its average volume of 937,828. The stock’s 50 day simple moving average is $32.81 and its 200 day simple moving average is $24.43. The company has a market cap of $2.81 billion, a P/E ratio of -19.75 and a beta of 0.12. Edgewise Therapeutics has a twelve month low of $8.49 and a twelve month high of $38.12.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its earnings results on Thursday, November 7th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.01.

Hedge Funds Weigh In On Edgewise Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of EWTX. Quest Partners LLC raised its stake in shares of Edgewise Therapeutics by 156.9% during the second quarter. Quest Partners LLC now owns 1,742 shares of the company’s stock valued at $31,000 after acquiring an additional 1,064 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Edgewise Therapeutics during the 2nd quarter worth about $35,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Edgewise Therapeutics by 21.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,392 shares of the company’s stock valued at $88,000 after buying an additional 604 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new stake in shares of Edgewise Therapeutics in the third quarter valued at about $161,000. Finally, Arizona State Retirement System acquired a new stake in shares of Edgewise Therapeutics in the second quarter valued at about $188,000.

Insiders Place Their Bets

In other Edgewise Therapeutics news, CMO Joanne M. Donovan sold 7,162 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $28.29, for a total value of $202,612.98. Following the sale, the chief marketing officer now owns 14,538 shares in the company, valued at $411,280.02. This trade represents a 33.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO R Michael Carruthers sold 125,092 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $28.57, for a total transaction of $3,573,878.44. Following the transaction, the chief financial officer now owns 6,904 shares of the company’s stock, valued at $197,247.28. This trade represents a 94.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 278,176 shares of company stock worth $7,893,316 over the last three months. Insiders own 24.11% of the company’s stock.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.